Bionomics Results Presentation Deck
PREVAIL was a Well Powered Phase 2 Study to Enable Further Development
The selected design allowed for iterative learnings to enable late-stage development
Questions that PREVAIL was designed to answer:
1 Efficacy
Is BNC210 pharmacologically active and efficacious?
2
3
4
5
6
7
11
Primary Outcome
Dose Response
Patient Population
Safety
Pharmacokinetics
Overall Design
Can the activity be captured by SUDS?
●
if yes, what is the best analytical methodology?
Is there a dose response differentiating 225 mg and 675 mg?
Is subject selection optimal? If no, how can it be improved?
Does the safety and tolerability profile support further development?
• If yes, is the profile compatible with a non-sedating anxiolytic?
Can the new BNC210 tablet formulation deliver a PK profile with rapid effect onset for
acute treatment of social anxiety?
Can the selected study design support late-stage development? If yes, how can the
overall design be improved?
BionomicsView entire presentation